Siegfried Biologics adds process development and GMP-manufacturing capabilities.
Avesta Biotherapeutics and Research (ABRPL) bought Siegfried Biologics to strengthen its position in the biopharmaceutical market. Siegfried Biologics is a Berlin-based CMO. The company’s experience lies in the development of biologics from cell line generation, upstream process development, and scale-up to GMP manufacturing.
While ABRPL, based in Bangalore, India, will conduct manufacturing services for the global market, its initial focus is on the BRIC (Brazil, Russia, India, China) markets. The company notes that these countries currently are dominated by small molecules. The Indian biopharmaceutical business, for example, is estimated at $1.5 billion. Yet, it is expected to grow to about $5 billion by 2010, dominated by recombinant proteins, vaccines, and mAbs, according to ABRPL.
ABRPL is a joint venture between Avesthagen and Meditab Specialities, which is a part of Cipla.
